Cartalax Injectable
Cartalax 20 mg contains the AED tripeptide (Ala-Glu-Asp), a synthetic bioregulator developed by Russian researcher Vladimir Khavinson for cartilage and connective tissue research. It belongs to the Khavinson short peptide class, which is investigated for proposed epigenetic mechanisms involving direct interaction with DNA and modulation of gene expression in target tissues.
In research contexts, Cartalax is studied for its potential effects on chondrocyte function and extracellular matrix regulation. A 2023 review published in Advances in Gerontology (PubMed-indexed, MEDLINE abstract available) evaluated the AED tripeptide (Kartalax) in osteoarthritis models and reported high efficacy in animal models of OA and oral administration in older patients with OA, regulating proapoptotic and proliferotropic molecules that form the SASP of chondrocytes. In vitro studies have suggested reduction of senescence markers (p16, p21, p53) and upregulation of SIRT6 in renal epithelial cell cultures.
In bodybuilding and joint health contexts, Cartalax is referenced anecdotally for supporting cartilage repair and joint comfort. However, no controlled human clinical trials with validated endpoints exist, and all published research originates from Russian institutes with no independent Western replication. Community reports of dosage protocols vary widely, and self-reported effects are confounded by concurrent use of other compounds. Such use falls outside any approved indication.
Research Properties of Cartalax 20 mg
- AED tripeptide sequence (Ala-Glu-Asp)
- Proposed epigenetic modulation of chondrocyte gene expression
- Investigated for anti-senescence effects in cell and animal models
- Studied for cartilage matrix maintenance and chondrocyte function
- 20 mg per vial for research applications
AED Tripeptide Bioregulator
Cartalax belongs to the Khavinson bioregulator class, a family of ultrashort peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology for proposed tissue-specific regulatory effects. The AED sequence (Ala-Glu-Asp) is specifically associated with cartilage and connective tissue in this research framework.
The proposed mechanism involves direct interaction with DNA and core histones after cellular penetration. Khavinson peptides are thought to bind to specific promoter regions, modulating chromatin accessibility and enabling transcription of genes associated with tissue homeostasis. Cartalax has been suggested to influence expression of ECM synthesis genes, proliferation markers (Ki-67, CD98hc), and matrix metalloproteinase-9 (MMP-9) in chondrocyte models.
Research has investigated Cartalax's effects on cellular senescence markers. Studies involving renal epithelial cell cultures have suggested reduction in p16, p21, and p53 expression, along with increased SIRT6, a sirtuin linked to longevity and genomic stability. These mechanisms remain investigational and have not been independently validated outside the originating research group.
Defining Characteristic
Proposed Epigenetic Mechanism
Cartalax is proposed to act through direct DNA interaction and gene expression modulation rather than cell-surface receptor binding. This epigenetic mechanism differs fundamentally from conventional cartilage medications and growth factor therapies.
Cartalax 20 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers several Khavinson bioregulators with different tissue targets. Cardiogen is the AEDP tetrapeptide targeting cardiac tissue. Bronchogen is the AEDL tetrapeptide for bronchial epithelium. Vesugen is the KED tripeptide for vascular endothelium. Cartalax's AED sequence is specifically directed toward cartilage and connective tissue.
Typical Dosage Ranges
Common reference ranges for Cartalax are derived primarily from Russian bioregulator protocols and community practices rather than controlled clinical trials. The Khavinson Institute protocol typically involves oral administration of 10–20 mg daily for 30 days, followed by a rest period of 3–6 months. Community protocols for injectable use reference 2–5 mg subcutaneously once daily for 4–12 week courses, but these are not validated by controlled trials.
| Use Case |
Common Reference Range |
Frequency |
| Khavinson Institute protocol (oral) |
10–20 mg |
Daily for 30 days |
| Community protocol (injectable) |
2–5 mg |
Daily for 4–12 weeks |
Reconstitution & Handling
Cartalax 20 mg is supplied as a lyophilized powder requiring reconstitution. Bacteriostatic Water is commonly referenced for reconstituting research peptides. A 20 mg vial reconstituted with 2 mL yields a concentration of 10 mg/mL. Add solvent slowly along the vial wall and swirl gently. Do not shake. Store reconstituted solution at 2–8°C and use within 30 days.
Stacking & Research Considerations
In Khavinson bioregulator protocols, Cartalax is sometimes referenced alongside other tissue-specific peptides. Epitalon (AEDG) shares three of four amino acids with Cartalax but targets the pineal gland and telomerase. Vesugen (KED) is sometimes referenced in combined protocols for joint and vascular support. However, no controlled studies have examined the safety or efficacy of these combinations.
Important
Individual Response Varies
The information above is for educational reference and does not constitute medical advice. Cartalax has not been evaluated by the FDA for safety or efficacy in humans.
Important Safety Information
No formal safety data exists for Cartalax from Western regulatory authorities. All published research originates from a single Russian research program, and no independent Western replication or controlled human trials have been conducted. The human record consists only of anecdotal self-reports with no adverse-event log.
Important
Non-Medical Use
Non-medical use of Cartalax falls outside any approved indication. Product purity does not establish that non-medical use is safe or appropriate for an individual. Material sold online is research-chemical grade, not pharmaceutical grade.
Potential Adverse Effects
Reported effects from community self-reports include gastrointestinal pressure and whole-body aches described as inflammatory after oral capsules, though these are unverified. Because Cartalax is proposed to interact with DNA and modulate gene expression, theoretical risks include unintended effects on cellular regulation. No systematic human safety data are available to characterize common or rare adverse effects.
Conditions Requiring Medical Evaluation
Individuals with active cancer, known hypersensitivity to peptide products, or pregnancy/breastfeeding status should exercise particular caution. No formal contraindication list exists for Cartalax because it has not undergone Western regulatory review.
Monitoring Considerations
If Cartalax is used in any research context, monitoring of joint function and inflammatory markers may be considered, though no standardized protocol exists. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Product Care
Storage & Handling
Store lyophilized powder at -20°C for long-term storage, protected from light and moisture. After reconstitution, store at 2–8°C and use within 30 days. Do not freeze reconstituted solution. Discard if solution becomes cloudy or develops particulate matter.
Keep all research peptides and injectable products out of the reach of children.
Further Safety Information
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is available
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Cartalax 20 mg product, use the security code on the vial label and cross-check it on the official Dragon Pharma site. Verify that the labelled sequence is Ala-Glu-Asp (AED) and that a certificate of analysis shows HPLC purity above 97 percent with mass spectrometry confirmation of the expected molecular weight (333.29 Da). Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Recommended Conditions
Store lyophilized powder at -20°C for long-term storage, protected from light and moisture. The unopened vial should be kept under conditions that preserve the peptide's structural integrity until reconstitution.
Once reconstituted, Cartalax solution should be stored at 2–8°C and used within 30 days. Do not freeze reconstituted solution. Discard if solution becomes cloudy or develops particulate matter.
Keep out of reach of children. Follow proper handling practices for research peptides and use appropriate sterile technique during reconstitution.
Quick Reference
Do & Don't
- Do store lyophilized powder at -20°C for long-term storage
- Do protect from light and moisture
- Do use reconstituted solution within 30 days
- Don't freeze reconstituted solution
- Don't expose to excessive heat
- Don't use if powder appears discolored
What is Cartalax 20 mg used for?
Cartalax 20 mg is a research peptide supplied as a lyophilized powder. It contains the AED tripeptide, which is investigated for proposed epigenetic effects on chondrocyte gene expression and cartilage tissue maintenance. There is no FDA-approved human indication for Cartalax.
How often should Cartalax 20 mg be administered?
Common reference ranges for Cartalax are derived from Russian bioregulator protocols. The Khavinson Institute protocol typically involves 10–20 mg daily for 30 days, followed by extended rest periods. Community injectable protocols reference 2–5 mg daily for 4–12 week courses.
Does Cartalax 20 mg require PCT?
Cartalax is not an anabolic steroid and does not suppress endogenous testosterone production. Post-cycle therapy designed for steroid cycles is not applicable. Its proposed epigenetic mechanism is distinct from hormonal suppression.
What does Cartalax do?
Cartalax is proposed to penetrate cell nuclei and interact with DNA to modulate gene expression in cartilage tissues. Research has suggested effects on ECM synthesis genes, proliferation markers, and senescence-associated proteins. These mechanisms remain investigational and have not been independently validated.
How long does Cartalax take to work?
No established onset timeline exists for Cartalax in humans because no controlled trials have been completed. Its proposed epigenetic mechanism would theoretically involve gene expression changes that develop over days to weeks, with effects potentially persisting after the peptide clears.
Is Cartalax the best joint peptide?
No single joint peptide is universally superior. Cartalax's research focus on cartilage and chondrocyte regulation is distinct from other peptides in Dragon Pharma's catalog. It has been indexed in PubMed and studied in Russian clinical contexts, but lacks independent Western validation.
What is the difference between Cartalax and Epitalon?
Cartalax (AED) and Epitalon (AEDG) are both Khavinson bioregulators, with Epitalon containing the full Cartalax sequence plus an additional glycine residue. They target different tissues: Cartalax focuses on cartilage, while Epitalon targets the pineal gland and telomerase.
What is the difference between Cartalax and Cardiogen?
Cartalax (AED) and Cardiogen (AEDP) are both Khavinson tetrapeptides but have different amino acid sequences and proposed tissue targets. Cartalax is associated with cartilage and connective tissue, while Cardiogen targets cardiac tissue.
Is 20 mg of Cartalax a lot?
20 mg is the total labeled content of the Cartalax 20 mg vial. Because no standardized human dosage exists for this research peptide, the milligram amount cannot be classified as high or low relative to established protocols. Khavinson protocols reference doses in the 10–20 mg range for oral use.
What strength is Cartalax 20 mg?
Cartalax 20 mg by Dragon Pharma contains 20 mg of Cartalax per vial as a lyophilized powder. The vial size is 2 mL. This is a research presentation.
Can Cartalax be stacked with other peptides?
In Khavinson bioregulator protocols, Cartalax is sometimes referenced alongside other tissue-specific peptides. Epitalon is the most commonly mentioned companion in combined longevity protocols. However, no controlled studies have examined these combinations.
No reviews found
Please log in to write Cartalax 20 mg review.
